Moderna Inc [MRNA] stock is trading at $55.22, up 0.77%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MRNA shares have gain 3.41% over the last week, with a monthly amount drifted -17.37%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on October 17, 2024, when Bernstein initiated its Mkt Perform rating and assigned the stock a price target of $55. Previously, Oppenheimer downgraded its rating to Perform on September 13, 2024. On September 13, 2024, downgrade downgraded it’s rating to Underweight and revised its price target to $70 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $65 on September 13, 2024. HSBC Securities upgraded its rating to a Hold but $82 remained the price target by the analyst firm on August 28, 2024. Deutsche Bank upgraded its rating to Hold for this stock on August 07, 2024, and downed its price target to $80. In a note dated August 05, 2024, RBC Capital Mkts downgraded an Sector Perform rating on this stock and revised its target price from $125 to $90.
Moderna Inc [MRNA] stock has fluctuated between $52.26 and $170.47 over the past year. Currently, Wall Street analysts expect the stock to reach $143.9 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $55.22 at the most recent close of the market. An investor can expect a potential return of 160.59% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Moderna Inc [NASDAQ:MRNA] reported sales of 5.04B for the trailing twelve months, which represents a drop of -29.94%. Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -0.92%, Pretax Profit Margin comes in at -0.86%, and Net Profit Margin reading is -1.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.45 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.17 points at the first support level, and at 53.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.98, and for the 2nd resistance point, it is at 58.74.
Ratios To Look Out For
For context, Moderna Inc’s Current Ratio is 4.09. Further, the Quick Ratio stands at 3.92, while the Cash Ratio is 1.05. Considering the valuation of this stock, the price to sales ratio is 4.21, the price to book ratio is 1.81.
Transactions by insiders
Recent insider trading involved Mock James M, Chief Financial Officer, that happened on Oct 07 ’24 when 715.0 shares were sold. Chief Legal Officer, Klinger Shannon Thyme completed a deal on Sep 09 ’24 to sell 551.0 shares. Meanwhile, Officer Klinger Shannon Thyme bought 551.0 shares on Sep 09 ’24.
